Trospium Treatment Effective for Overactive Bladder

Men with overactive bladder benefit from trospium treatment with low risk of urinary retention

THURSDAY, Jan. 27 (HealthDay News) -- Treatment with trospium chloride extended-release (XR) in men with an overactive bladder (OAB) is effective and safe, according to a study published in the January issue of Urology.

Scott A. MacDiarmid, M.D., from Alliance Urology Specialists in Greensboro, N.C., and colleagues analyzed data from 176 male patients suffering from OAB, who were participating in double blind, randomized, placebo controlled studies. During a 12-week period, 94 men were treated daily with 60 mg trospium XR, and 82 received a placebo.

The researchers found that treatment with trospium XR resulted in a decreased mean number of daily toilet voids (P = 0.05) and episodes of urinary incontinence (P = 0.05) after 12 weeks. Twenty percent of patients treated with trospium XR and 18.3 percent receiving placebo suffered from at least one adverse event, which may have been related to the medication. Urinary retention was noted in two patients treated with trospium XR, both of whom were 75 years of age or older, and one of whom suffered from prostate enlargement.

"Based on our study results trospium XR is safe and effective in men with OAB. The risk of urinary retention is low and may be further decreased by careful patient selection," the authors write.

The authors disclosed financial support for this study from Allergan and Endo Pharmaceuticals.

Full Text (subscription or payment may be required)

Physician's Briefing